RxDoctor Payments Data

Ruth Shaffer

Family · Berlin, PANPI 1528442985

Payments from drug & device makers

$685in general payments, 2019–2025

Across 38 payments — averaging $18.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$104
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$97
  • Novo Nordisk$74
  • Merck$73
  • Lilly USA, LLC$55
  • Inari Medical, Inc.$55
  • plus $227 from 10 others

What the payments were for

  • Food & beverage$685100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$685 in reported general payments places this provider in the 65th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$46,494
Medicare patients
153
Services billed
708

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide93$103,890
OzempicSemaglutide79$100,695
JardianceEmpagliflozin60$65,709
TradjentaLinagliptin42$32,888
EliquisApixaban31$26,506
FarxigaDapagliflozin Propanediol18$22,609
JanuviaSitagliptin Phosphate35$22,595
ProliaDenosumab11$19,030
Lantus SolostarInsulin Glargine,hum.Rec.Anlog56$8,119
Atorvastatin Calcium478$7,287
XareltoRivaroxaban12$6,284
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$4,741
Levothyroxine Sodium275$3,241
SynthroidLevothyroxine Sodium37$2,793
Rosuvastatin Calcium85$2,215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$55$103,89093 claims
Novo NordiskOzempic$74$100,69579 claims
MerckJanuvia$73$22,59535 claims
AbbVieSynthroid$33$2,79337 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,717 family providers in Pennsylvania.

Other family in Berlin

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →